NEWS
Paul Hastings Advises Aktis Oncology on Its Upsized $317.7 Millon IPO
January 09, 2026
Paul Hastings LLP advised Aktis Oncology (Nasdaq: AKTS), a clinical-stage biotechnology company developing radiopharmaceuticals for cancer treatment, on its upsized $317.7 million initial public offering of 17,650,000 shares of common stock at $18 per share. Aktis has also granted the underwriters a 30-day option to purchase up to 2,647,500 additional shares at the initial public offering price. The offering is expected to close on or about Jan. 12, 2026, subject to customary closing conditions.
The transaction represents the first biotech IPO of 2026.
Equity Capital Markets and Corporate Life Sciences chair Seo Salimi and partner Will Magioncalda led the Paul Hastings team, which included associates Chris Guerin and Adam Swank.
More details can be found here.
About Paul Hastings
With widely recognized elite teams across 17 core practices, Paul Hastings is a premier law firm with a culture of excellence focused on providing intellectual capital and superior execution globally to the world’s leading investment banks, asset managers and corporations.